$32.360
-0.434 (-1.34%)收盘时
VTVT 资讯
VTVT 事件
vTv Therapeutics Launches New Drug cadisegliatin for T1D
"Cadisegliatin has been specifically designed to address the significant unmet need of hypoglycemia, a major limiting factor in achieving optimal blood glucose control in T1D," said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. "We look forward to discussing cadisegliatin's potential with leading experts in T1D at our planned fourth-quarter KOL event. With cash runway through our anticipated topline data readout, we are focused on advancing development of the potential first oral adjunctive therapy for people with T1D."
vTv Therapeutics Q1 Revenue Reaches $36.84M
Reports Q1 revenue $36.84M, consensus $10M. "We are executing with focus and discipline as we advance cadisegliatin, a potentially transformative, first-in-class oral therapy for people living with type 1 diabetes," said Paul Sekhri, chairman, president, and CEO of vTv Therapeutics. "Enrollment in our Phase 3 CATT1 trial continues to progress steadily, supported by expanded site activation and strong engagement from both investigators and patients. Importantly, with our recently strengthened balance sheet, we are well-capitalized to deliver on completion of enrollment and the anticipated topline data readout and drive long-term value for shareholders."
vTv Therapeutics Cash Position Increases to $88.9M
The company's cash position as of December 31, 2025, was $88.9M compared to $36.7M as of December 31, 2024. "In 2025, vTv delivered meaningful clinical and corporate progress that positions us for a highly productive 2026," said Paul Sekhri, chairman, president and CEO of vTv Therapeutics. "During the course of the year, we initiated patient dosing in the Phase 3 CATT1 trial evaluating cadisegliatin as an adjunct to insulin for the treatment of type 1 diabetes, strengthened our balance sheet with an $80.0 million financing with leading healthcare investors, and continued to expand our intellectual property estate supporting cadisegliatin. In early 2026, we secured an additional $20.0 million in non-dilutive funding."
vTv Therapeutics Expands License Agreement with Newsoara
vTv Therapeutics announced that it has expanded its license agreement with Newsoara Biopharma to provide Newsoara with global rights to the Company's PDE4 inhibitor, HPP737. Pursuant to the amended license agreement, Newsoara has obtained an exclusive, worldwide license to develop and commercialize Company's PDE4 inhibitor, HPP737, in exchange for an upfront payment and potential future milestone payments and royalties on net sales. In addition to the upfront payment of $20 million, the amended license with Newsoara includes future development milestones of up to approximately $50 million, future sales milestones of up to $65 million, and tiered royalties based on sales.
vTv Therapeutics Submits Phase 2 Study Protocol for Diabetes Drug
vTv Therapeutics announced a Phase 2 clinical study protocol developed in collaboration with M42's Insights Research Organization & Solutions, a United Arab Emirates-based contract research organization, has been submitted to the Department of Health Abu Dhabi. The study is designed to evaluate the safety and efficacy of cadisegliatin, an oral adjunctive therapy to insulin, in people living with type 2 diabetes. This study constitutes the longest trial investigating cadisegliatin to date and will be a 12-month, double-blind, randomized, placebo-controlled trial enrolling approximately 300 patients with type 2 diabetes who are treated with insulin for glycemic control. Participants will be randomized into three arms: two cadisegliatin dose groups and a placebo control group. The trial will take place in the UAE, Jordan, and Tunisia, with the first patient first visit expected in the first quarter of 2026.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。